Depletion of the novel p53-target gene carnitine palmitoyltransferase 1C delays tumor growth in the neurofibromatosis type i tumor model

Cell Death and Differentiation

Volumn 20, Issue 4, 2013, Pages 659-668

  Sanchez Macedo, N ^a   Feng, J ^a   Faubert, B ^b   Chang, N ^a   Elia, A ^c,d   Rushing, E J ^a   Tsuchihara, K ^c,d,f   Bungard, D ^e   Berger, S L ^e   Jones, R G ^b   Mak, T W ^c,d   Zaugg, K ^a,c,d  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b MCGILL UNIVERSITY   (Canada)

^c PRINCESS MARGARET HOSPITAL   (Canada)

^d UNIVERSITY HEALTH NETWORK   (Canada)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

^f NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

Author keywords

AMPK; Carcinogenesis; Carnitine palmitoyltransferase; Metabolism; P53

Indexed keywords

CARNITINE PALMITOYLTRANSFERASE 1C; CARNITINE PALMITOYLTRANSFERASE I; GLUCOSE; MESSENGER RNA; NEUROFIBROMIN; PROTEIN P53; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CARCINOGENESIS; CELL DEATH; CELL HYPOXIA; CELL PROLIFERATION; CELL PROTECTION; CELL SURVIVAL; CONTROLLED STUDY; EMBRYO; ENZYME PHOSPHORYLATION; GENE OVEREXPRESSION; GENE TARGETING; IN VITRO STUDY; IN VIVO STUDY; INTRON; METABOLIC STRESS; MOUSE; NEUROFIBROMATOSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR GROWTH; UPREGULATION;

AMP-ACTIVATED PROTEIN KINASES; ANIMALS; BRAIN; CARNITINE O-PALMITOYLTRANSFERASE; CELL HYPOXIA; CELL LINE; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MITOCHONDRIA; NEUROFIBROMATOSIS 1; NEUROFIBROMIN 1; PROMOTER REGIONS, GENETIC; RNA, MESSENGER; TRANSCRIPTION, GENETIC; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION;

MURINAE;

EID: 84874947662     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/cdd.2012.168     Document Type: Article

References (41)

1. Harris AL. Hypoxia-a key regulatory factor in tumour growth. Nat Rev Cancer 2002; 2: 38-47.
2. Brown JM, Wilson WR. Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer 2004; 4: 437-447.
3. Shaw RJ. Glucose metabolism and cancer. Curr Opin Cell Biol 2006; 18: 598-608.
4. Barger JF, Plas DR. Balancing biosynthesis and bioenergetics: metabolic programs in oncogenesis. Endocr Relat Cancer 2010; 17: R287-R304.
5. Menendez JA, Lupu R. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat Rev Cancer 2007; 7: 763-777.
6. Flavin R, Peluso S, Nguyen PL, Loda M. Fatty acid synthase as a potential therapeutic target in cancer. Future Oncol 2010; 6: 551-562.
7. Zaugg K, Yao Y, Reilly PT, Kannan K, Kiarash R, Mason J et al. Carnitine palmitoyltransferase 1C promotes cell survival and tumor growth under conditions of metabolic stress. Genes Dev 2011; 25: 1041-1051.
8. Wolfgang MJ, Cha SH, Millington DS, Cline G, Shulman GI, Suwa A et al. Brain-specific carnitine palmitoyl-transferase-1c: role in CNS fatty acid metabolism, food intake, and body weight. J Neurochem 2008; 105: 1550-1559.
9. Wolfgang MJ, Lane MD. Control of energy homeostasis: role of enzymes and intermediates of fatty acid metabolism in the central nervous system. Annu Rev Nutr 2006; 26: 23-44.
10. Reamy AA, Wolfgang MJ. Carnitine palmitoyltransferase-1c gain-of-function in the brain results in postnatal microencephaly. J Neurochem 2011; 118: 388-398.
11. Hardie DG, Ross FA, Hawley SA. AMPK: a nutrient and energy sensor that maintains energy homeostasis. Nat Rev Mol Cell Biol 2012; 13: 251-262.
12. Hardie DG. AMP-activated protein kinase: an energy sensor that regulates all aspects of cell function. Genes Dev 2011; 25: 1895-1908.
13. Jones RG, Plas DR, Kubek S, Buzzai M, Mu J, Xu Y et al. AMP-activated protein kinase induces a p53-dependent metabolic checkpoint. Mol Cell 2005; 18: 283-293.
14. Sierra AY, Gratacos E, Carrasco P, Clotet J, Urena J, Serra D et al. CPT1c is localized in endoplasmic reticulum of neurons and has carnitine palmitoyltransferase activity. J Biol Chem 2008; 283: 6878-6885.
15. Prestridge DS. Predicting Pol II promoter sequences using transcription factor binding sites. J Mol Biol 1995; 249: 923-932.
16. Tsunoda T, Takagi T. Estimating transcription factor bindability on DNA. Bioinformatics 1999; 15: 622-630.
17. Bungard D, Fuerth BJ, Zeng PY, Faubert B, Maas NL, Viollet B et al. Signaling kinase AMPK activates stress-promoted transcription via histone H2B phosphorylation. Science 2010; 329: 1201-1205.
18. Reilly KM, Loisel DA, Bronson RT, McLaughlin ME, Jacks T. Nf1;Trp53 mutant mice develop glioblastoma with evidence of strain-specific effects. Nat Genet 2000; 26: 109-113.
19. Vogel KS, Klesse LJ, Velasco-Miguel S, Meyers K, Rushing EJ, Parada LF. Mouse tumor model for neurofibromatosis type 1. Science 1999; 286: 2176-2179.
20. Buchstaller J, McKeever PE, Morrison SJ. Tumorigenic cells are common in mouse MPNSTs but their frequency depends upon tumor genotype and assay conditions. Cancer Cell 2012; 21: 240-252.
21. Cichowski K, Shih TS, Schmitt E, Santiago S, Reilly K, McLaughlin ME et al. Mouse models of tumor development in neurofibromatosis type 1. Science 1999; 286: 2172-2176.
22. Price N, van der Leij F, Jackson V, Corstorphine C, Thomson R, Sorensen A et al. A novel brain-expressed protein related to carnitine palmitoyltransferase I. Genomics 2002; 80: 433-442.
23. Carrasco P, Sahun I, McDonald J, Ramirez S, Jacas J, Gratacos E et al. Ceramide Levels Regulated by Carnitine Palmitoyltransferase 1C Control Dendritic Spine Maturation and Cognition. J Biol Chem 2012; 287: 21224-21232.
24. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000; 408: 307-310.
25. Horn HF, Vousden KH. Coping with stress: multiple ways to activate p53. Oncogene 2007; 26: 1306-1316.
26. Koumenis C, Alarcon R, Hammond E, Sutphin P, Hoffman W, Murphy M et al. Regulation of p53 by hypoxia: dissociation of transcriptional repression and apoptosis from p53- dependent transactivation. Mol Cell Biol 2001; 21: 1297-1310.
27. Graeber TG, Peterson JF, Tsai M, Monica K, Fornace Jr AJ, Giaccia AJ. Hypoxia induces accumulation of p53 protein, but activation of a G1-phase checkpoint by low-oxygen conditions is independent of p53 status. Mol Cell Biol 1994; 14: 6264-6277.
28. Lowe SW, Cepero E, Evan G. Intrinsic tumour suppression. Nature 2004; 432: 307-315.
29. Vousden KH, Ryan KM. p53 and metabolism. Nat Rev Cancer 2009; 9: 691-700.
30. Matoba S, Kang JG, Patino WD, Wragg A, Boehm M, Gavrilova O et al. p53 regulates mitochondrial respiration. Science 2006; 312: 1650-1653.
31. Bensaad K, Tsuruta A, Selak MA, Vidal MN, Nakano K, Bartrons R et al. TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell 2006; 126: 107-120.
32. Jones RG, Thompson CB. Tumor suppressors and cell metabolism: a recipe for cancer growth. Genes Dev 2009; 23: 537-548.
33. Deberardinis RJ, Lum JJ, Thompson CB. Phosphatidylinositol 3-kinase-dependent modulation of carnitine palmitoyltransferase 1A expression regulates lipid metabolism during hematopoietic cell growth. J Biol Chem 2006; 281: 37372-37380.
34. Hardie DG, Hawley SA, Scott JW. AMP-activated protein kinase-development of the energy sensor concept. J Physiol 2006; 574(Pt 1): 7-15.
35. Bonnefont JP, Djouadi F, Prip-Buus C, Gobin S, Munnich A, Bastin J. Carnitine palmitoyltransferases 1 and 2: biochemical, molecular and medical aspects. Mol Aspects Med 2004; 25: 495-520.
36. Wolfgang MJ, Lane MD. Hypothalamic malonyl-CoA and CPT1c in the treatment of obesity. FEBS J 2011; 278: 552-558.
37. Jeon SM, Chandel NS, Hay N. AMPK regulates NADPH homeostasis to promote tumour cell survival during energy stress. Nature 2012; 485: 661-665.
38. Tsuchihara K, Lapin V, Bakal C, Okada H, Brown L, Hirota-Tsuchihara M et al. Ckap2 regulates aneuploidy, cell cycling, and cell death in a p53-dependent manner. Cancer Res 2005; 65: 6685-6691.
39. Henry KW, Wyce A, Lo WS, Duggan LJ, Emre NC, Kao CF et al. Transcriptional activation via sequential histone H2B ubiquitylation and deubiquitylation, mediated by SAGA-associated Ubp8. Genes Dev 2003; 17: 2648-2663.
40. Skinnider BF, Elia AJ, Gascoyne RD, Trumper LH, von Bonin F, Kapp U et al. Interleukin 13 and interleukin 13 receptor are frequently expressed by Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma. Blood 2001; 97: 250-255.
41. Hui CC, Joyner AL. A mouse model of greig cephalopolysyndactyly syndrome: the extra-toesJ mutation contains an intragenic deletion of the Gli3 gene. Nat Genet 1993; 3: 241-246.